Posted by Michael Wonder on 15 Dec 2020
Roche launches cobas PIK3CA mutation test for patients with advanced or metastatic breast cancer in countries accepting the CE mark
15 December 2020 - This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer.
Roche today announced the launch of the cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer.
Previously only available as research use only, this in vitro diagnostic test is now available in countries accepting the CE mark.
